In this article, we will list the Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential. Please visit Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential if you would like to see the extended list and the methodology behind it.
5. Wave Life Sciences Ltd (NASDAQ:WVE)
Maverick Capital Equity Stake: $73.67 Million
Number of Hedge Fund Holders: 42
Stock Upside Potential: 269.24%
Wave Life Sciences Ltd (NASDAQ:WVE) is one of billionaire Lee Ainslie’s stocks with huge upside potential. Analysts expect Wave Life Sciences shares to explode by almost 270% over the next 12 months.
On May 20, Wells Fargo raised its price target on Wave Life Sciences shares to $14 from $13 while keeping an Overweight rating on the stock. For this action, Wells Fargo cited updated data from the company’s AATD program WVE-006.
Photo by AlphaTradeZone on Pexels
Wave Life Sciences Ltd (NASDAQ:WVE) reported updated data from the ongoing RestorAATion-2 trial of WVE-006 on May 18. The company said the data affirm WVE-006’s potential to address both lung and liver AATD with convenient, safe, and durable therapy.
According to Wave Life Sciences, the only approved treatment for AATD addresses only lung disease, while there is no approved treatment for AATD liver disease. The company said it was on track for feedback from the FDA on a potential accelerated pathway for WVE-006 in mid-2026.
Wave’s RestorAATion-2 trial of WVE-006 includes both single ascending dose and multiple ascending dose portions. Wells Fargo noted that the 600mg single-ascending dose showed improved results and that the 600mg multiple-ascending dose could deliver better efficacy.
Wave Life Sciences Ltd (NASDAQ:WVE) is a biotechnology company based in Massachusetts. The company is developing RNA medicines for a wide range of health conditions. Its pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, liver disease, Duchenne muscular dystrophy, and Huntington’s disease.
4. GFL Environmental Inc (NYSE:GFL)
Maverick Capital Equity Stake: $160.61 Million
Number of Hedge Fund Holders: 44
Stock Upside Potential: 58.26%
GFL Environmental Inc (NYSE:GFL) is one of billionaire Lee Ainslie’s stocks with huge upside potential. On May 11, Stifel reaffirmed its Buy rating on GFL Environmental Inc (NYSE:GFL) stock with a price target of $65.
For this call, the firm cited expected benefits from GFL Environmental’s acquisition of Secure Waste. This followed a recent dinner with the executives from both companies.
According to Stifel, the deal looks financially favorable for GFL Environmental. It could bolster GFL’s financial metrics and debt capacity, potentially making it easier for the company to fund future acquisitions.
Secure Waste is a leading waste management provider in Western Canada and North Dakota. It operates 12 landfills, 12 recycling facilities, and 55 waste treatment facilities. Stifel noted that for GFL, this acquisition represents an investment in Western Canada’s long-term growth potential.
GFL Environmental agreed to acquire Secure Waste for roughly C$6.4 billion, and it plans to pay for the transaction with a combination of stock and cash. The cash component of the transaction will be funded with cash on hand, a bridge facility, and a revolving credit facility. GFL Environmental has obtained full financing commitment for this transaction.
GFL Environmental Inc (NYSE:GFL) is a waste management company operating in the US and Canada. It provides solid waste collection, recycling, and disposal services. The company serves municipal, residential, industrial, and institutional customers.
3. Repligen Corp (NASDAQ:RGEN)
Maverick Capital Equity Stake: $178.95 Million
Number of Hedge Fund Holders: 40
Stock Upside Potential: 41.26%
Repligen Corp (NASDAQ:RGEN) is one of billionaire Lee Ainslie’s stocks with huge upside potential. Analysts see Repligen stock soaring more than 40% from its current level.
On May 15, RBC Capital resumed coverage on Repligen Corp (NASDAQ:RGEN) stock with an Outperform rating and a price target of $160. The firm cited the company’s growth potential, noting the diversity of Repligen’s growth drivers and the strengthening bioprocess market.
According to the firm, these factors should enable Repligen to return to mid-teens organic sales growth. Additionally, RBC Capital cited several tailwinds, including commercial mix and biosimilars.
Repligen’s Q1 2026 results showed a strong start to the year. Revenue increased 15% YoY to $194 million and exceeded analysts’ forecast of $192.1 million. Adjusted EPS rose to $0.48 from $0.39 a year ago and beat the consensus estimate of $0.38.
Looking ahead, Repligen reaffirmed its full-year 2026 revenue and adjusted EPS guidance. It anticipated full-year revenue in the range of $803 million to $833 million, reflecting a growth of 9% to 13%. It expects adjusted EPS in the band of $1.97 to $2.05. Repligen CEO Olivier Loeillot said their focus right now is on accelerating profitable growth.
Repligen Corp (NASDAQ:RGEN) is a bioprocessing company. It develops and manufactures products used by pharmaceutical companies to produce biological drugs. Repligen’s products and technologies are designed to make biological drug manufacturing more efficient and cost-effective.
2. Boston Scientific Corp (NYSE:BSX)
Maverick Capital Equity Stake: $263.24 Million
Number of Hedge Fund Holders: 106
Stock Upside Potential: 70.50%
Boston Scientific Corp (NYSE:BSX) is one of billionaire Lee Ainslie’s stocks with huge upside potential. Analysts see more than 70% upside potential in Boston Scientific stock from the current level.
Boston Scientific Corp (NYSE:BSX) achieved strong results from a pivotal study evaluating its SEISMIQ 4CE catheter in patients with severely calcified coronary artery disease. On May 19, the company reported that the study met its primary safety and efficacy endpoints with high rates of success.
At 30 days of treatment, the safety endpoint was met with a 93.3% success rate, exceeding a goal of 86.2%. The efficacy endpoint was met with a 93.7% success rate, well above a goal of 85.8%.
Boston Scientific’s SEISMIQ 4CE catheter is an intravascular lithotripsy (IVL) device. According to the company, the study results provide pivotal evidence to support regulatory submission for the SEISMIQ 4CE catheter. The company says this device may provide physicians with a new, differentiated treatment option and improve the outcomes for high-risk patients.
The pivotal study, dubbed FRACTURE, enrolled 420 patients with severe calcified coronary artery disease. These patients will be followed for two years after their procedure.
Boston Scientific Corp (NYSE:BSX) is a medical technology company founded in 1979 and based in Massachusetts. It provides medical devices used to diagnose and treat a wide range of health conditions. Boston Scientific devices are widely used in medical specialties like cardiology, neurology, and urology.
1. Nvidia Corp (NASDAQ:NVDA)
Maverick Capital Equity Stake: $553.71 Million
Number of Hedge Fund Holders: 275
Stock Upside Potential: 40.50%
Nvidia Corp (NASDAQ:NVDA) is one of billionaire Lee Ainslie’s stocks with huge upside potential. The stock has gained more than 23% over the past six months and soared over 60% over the past year. Analysts continue to see upside in Nvidia stock.
On June 2, Wolfe Research cautioned that the market’s $360 billion surge in Nvidia Corp (NASDAQ:NVDA) and Arm Holdings’ combined value following Nvidia’s PC chip reveal at Computex was an overreaction, citing limited commercial potential.
Analyst Chris Caso noted the RTX Spark chip, co‑developed with MediaTek and priced above $2,500, targets a narrow segment, while Qualcomm’s Snapdragon X Elite has struggled in the $1,000–$1,500 range since 2024. Wolfe argued the math equating to $1.3 billion in market cap for every PC sold annually is difficult to justify, tempering enthusiasm around Nvidia’s entry into the PC market.
Separately, on May 31, Microsoft unveiled the Surface Laptop Ultra, developed in partnership with Nvidia and set to launch later this year. Designed for power users, the 15‑inch touchscreen device includes a large trackpad and multiple connectivity options such as USB‑A, USB‑C, HDMI, and a card reader. Positioned for AI professionals, developers, and creators, the laptop aims to deliver advanced performance for demanding workloads.
At its core, the Surface Ultra features Nvidia’s RTX Spark superchip, combining a Blackwell GPU with a 20‑core Arm‑based Grace CPU. Offering 1 petaflop of AI compute and the ability to run models with up to 120 billion parameters locally, the device underscores Nvidia’s push into the PC market. CEO Jensen Huang has highlighted this move as part of a broader $200 billion CPU opportunity, signaling Nvidia’s ambition to expand beyond GPUs into high‑performance computing for professionals.
Nvidia Corp (NASDAQ:NVDA) is a global semiconductor company. It develops graphics processing units and a variety of other chips for various applications. Nvidia chips are widely used in high-performance computing, AI systems, and automotive applications.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Data Center Stocks to Invest In According to Billionaires and 10 Best Debt-Free IT Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
